Latest news
Dr Brufsky on the FDA Approval of Gedatolisib Plus Fulvestrant ± Palbociclib in PIK3CA Wild-Type Breast Cancer - OncLiveOncLive · Fri, 07 Aug 2026 03:24:28 GMTFDA Flashback: Breast Cancer Decisions and News From July 2026 - OncLiveOncLive · Thu, 06 Aug 2026 22:03:53 GMTNCCN Guidelines Add Gedatolisib-Based Regimens for Pretreated PIK3CA Wild-Type Advanced Breast Cancer - OncLiveOncLive · Mon, 03 Aug 2026 15:13:18 GMTGedatolisib/Fulvestrant Earns NCCN Category 1 Listing for HR+/HER2- Breast Cancer - CancerNetworkCancerNetwork · Mon, 03 Aug 2026 12:08:52 GMTGedatolisib Combinations Nearly Double PFS in PIK3CA-Mutant Breast Cancer - Targeted OncologyTargeted Oncology · Sun, 02 Aug 2026 15:05:39 GMTNCCN Lists Gedatolisib Regimens as Preferred Option in HR+/HER2– Metastatic Breast Cancer - Targeted OncologyTargeted Oncology · Fri, 31 Jul 2026 15:09:03 GMTNewly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer - Yahoo FinanceYahoo Finance · Thu, 30 Jul 2026 12:30:00 GMTBehind the Gedatolisib FDA Approval: An Investigator's Perspective on HR+ Breast Cancer - Targeted OncologyTargeted Oncology · Tue, 28 Jul 2026 07:00:00 GMT